

Pembrolizumab KEYNOTE-826

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Pembrolizumab KEYNOTE-826

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Gynaecological Malignancies  
 Therapeutic Indication: Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS  $\geq 1$   
 Experimental Arm: Pembrolizumab + ChT with or without bevacizumab  
 Control Arm: Placebo + ChT with or without bevacizumab

